Research
Hormonal
CagriSema (semaglutide + cagrilintide) produces superior weight loss (22.7% at 68 weeks) compared to semaglutide 2.4 mg alone (16.1%) or cagrilintide alone (11.8%).
If you have obesity and need maximum weight loss, ask your doctor about CagriSema. It combines two hormones (GLP-1 and amylin) into one weekly injection. Clinical trials show it can help you lose nearly 23% of your body weight, which is more than semaglutide or tirzepatide alone. It is currently in Phase 3 trials.
WeakSupportsHIGH confidence
The recently announced topline results from REDIFINE 1 trial showed weight loss of 22.7% with cagrisema after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo
Why this rating
Based on Phase 3 REDIFINE 1 trial.
Source
ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update (2025)
Sri Venkata Madhu et al. · Indian Journal of Endocrinology and Metabolism · 2025
DOI 10.4103/ijem.ijem_680_25
clinical_guidelineCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- South Asian ethnicity is predisposed to 'thin-fat' obesity (normal weight obesity), leading to higher risks of diabetes, hypertension, and dyslipidemia at lower BMIs.Limited
- Injectable semaglutide 2.4 mg once weekly produces significant weight loss (mean 15.2% over 104 weeks) and improves cardiometabolic risk factors in adults with obesity.Weak
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss (up to 20.9% with 15 mg weekly dose) and is recommended for patients targeting 15-20% weight loss.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →